ZA200602133B - Novel salt of donepezil and its polymorphs (donepezi oxalate) - Google Patents

Novel salt of donepezil and its polymorphs (donepezi oxalate) Download PDF

Info

Publication number: ZA200602133B
Authority: ZA; South Africa
Prior art keywords: matter; composition; solvent; oxalate; donepezil
Prior art date: 2004-06-29

Application number

ZA200602133A

Other languages

English (en)

Inventor

Tarur Venkatasubramanian Radhakrishnan

Sathe Dhananja Govind

Naidu Avinash Venkataraman

Original Assignee

Usv Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-06-29

Filing date

2006-03-14

Publication date

2007-06-27

2006-03-14 Application filed by Usv Ltd filed Critical Usv Ltd

2007-06-27 Publication of ZA200602133B publication Critical patent/ZA200602133B/en

Links

ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 title claims abstract description 87
229960003530 donepezil Drugs 0.000 title claims abstract description 56
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 title claims description 82
150000003839 salts Chemical class 0.000 title description 3
238000000034 method Methods 0.000 claims abstract description 20
150000003891 oxalate salts Chemical class 0.000 claims abstract description 11
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 47
239000002904 solvent Substances 0.000 claims description 36
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 32
239000000203 mixture Substances 0.000 claims description 30
239000011541 reaction mixture Substances 0.000 claims description 23
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 21
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 21
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 19
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 18
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 18
238000000634 powder X-ray diffraction Methods 0.000 claims description 16
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
238000000862 absorption spectrum Methods 0.000 claims description 12
238000006243 chemical reaction Methods 0.000 claims description 12
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
235000006408 oxalic acid Nutrition 0.000 claims description 11
230000008569 process Effects 0.000 claims description 11
238000001704 evaporation Methods 0.000 claims description 9
239000012296 anti-solvent Substances 0.000 claims description 8
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 7
238000004519 manufacturing process Methods 0.000 claims description 7
238000002441 X-ray diffraction Methods 0.000 claims description 6
238000001228 spectrum Methods 0.000 claims description 6
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 claims description 5
239000000047 product Substances 0.000 claims description 5
208000024827 Alzheimer disease Diseases 0.000 claims description 4
238000002156 mixing Methods 0.000 claims description 4
239000002244 precipitate Substances 0.000 claims description 4
239000008194 pharmaceutical composition Substances 0.000 claims description 3
206010039966 Senile dementia Diseases 0.000 claims description 2
239000003814 drug Substances 0.000 claims description 2
BSFODEXXVBBYOC-UHFFFAOYSA-N 8-[4-(dimethylamino)butan-2-ylamino]quinolin-6-ol Chemical compound C1=CN=C2C(NC(CCN(C)C)C)=CC(O)=CC2=C1 BSFODEXXVBBYOC-UHFFFAOYSA-N 0.000 claims 1
201000010099 disease Diseases 0.000 claims 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
239000000843 powder Substances 0.000 claims 1
PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 abstract description 8
238000002360 preparation method Methods 0.000 abstract description 7
239000013078 crystal Substances 0.000 description 44
238000003756 stirring Methods 0.000 description 32
150000001875 compounds Chemical class 0.000 description 25
238000002844 melting Methods 0.000 description 18
230000008018 melting Effects 0.000 description 18
IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 17
238000007792 addition Methods 0.000 description 15
238000001914 filtration Methods 0.000 description 15
238000001035 drying Methods 0.000 description 14
238000010438 heat treatment Methods 0.000 description 13
238000000926 separation method Methods 0.000 description 12
235000019439 ethyl acetate Nutrition 0.000 description 10
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
238000001816 cooling Methods 0.000 description 6
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
238000005574 benzylation reaction Methods 0.000 description 4
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
-1 acetone Chemical class 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
239000007787 solid Substances 0.000 description 2
ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
UCTLHLZWKJIXJI-LXIBVNSESA-N [(3s,8r,9s,10r,13s,14s)-17-chloro-16-formyl-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15-decahydro-1h-cyclopenta[a]phenanthren-3-yl] acetate Chemical compound C([C@@H]12)C[C@]3(C)C(Cl)=C(C=O)C[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)C)C1 UCTLHLZWKJIXJI-LXIBVNSESA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
238000009472 formulation Methods 0.000 description 1
150000008282 halocarbons Chemical class 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
150000002825 nitriles Chemical class 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
- C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Hydrogenated Pyridines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

ZA200602133A 2004-06-29 2006-03-14 Novel salt of donepezil and its polymorphs (donepezi oxalate) ZA200602133B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US10/879,816 US7439365B2 (en)	2003-11-17	2004-06-29	Pharmaceutical salt of (1-benzyl-4-[(5,6-dimethoxy-1-indanone)-2-yl] methyl piperidine (Donepezil)

Publications (1)

Publication Number	Publication Date
ZA200602133B true ZA200602133B (en)	2007-06-27

Family

ID=34959819

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200602133A ZA200602133B (en)	2004-06-29	2006-03-14	Novel salt of donepezil and its polymorphs (donepezi oxalate)

Country Status (15)

Country	Link
US (1)	US7439365B2 (pt)
EP (1)	EP1761492B1 (pt)
JP (1)	JP2007536209A (pt)
KR (1)	KR20060090245A (pt)
CN (1)	CN1874998A (pt)
AT (1)	ATE448203T1 (pt)
AU (1)	AU2004320911A1 (pt)
CA (1)	CA2549752C (pt)
DE (1)	DE602004024129D1 (pt)
EA (1)	EA200700150A1 (pt)
ES (1)	ES2336572T3 (pt)
PL (1)	PL1761492T3 (pt)
PT (1)	PT1761492E (pt)
WO (1)	WO2006001031A1 (pt)
ZA (1)	ZA200602133B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HUP0401850A3 (en) *	2004-09-15	2008-03-28	Egis Gyogyszergyar Nyilvanosan	Donepezil salts for producing pharmaceutical composition
DE102004046497A1 (de) *	2004-09-23	2006-04-06	Helm Ag	Donepezil-Salze
US7592459B2 (en) *	2004-09-29	2009-09-22	Chemagis Ltd.	Use of purified donepezil maleate for preparing pharmaceutically pure amorphous donepezil hydrochloride
WO2006063025A1 (en) *	2004-12-07	2006-06-15	Nektar Therapeutics	Stable non-crystalline formulation comprising donepezil
US20060280789A1 (en) *	2004-12-27	2006-12-14	Eisai Research Institute	Sustained release formulations
US20090208579A1 (en) *	2004-12-27	2009-08-20	Eisai R & D Management Co., Ltd.	Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
EP1830886B1 (en) *	2004-12-27	2016-04-13	Eisai R&D Management Co., Ltd.	Method for stabilizing anti-dementia drug
US20060246003A1 (en) *	2004-12-27	2006-11-02	Eisai Co. Ltd.	Composition containing anti-dementia drug
HU227474B1 (en) *	2005-12-20	2011-07-28	Richter Gedeon Nyrt	Process for industrial scale production of high purity donepezil hydrochloride polymorph i.
US20100113793A1 (en) *	2006-03-20	2010-05-06	Ind-Swift Laboratories Limited	Process for the Preparation of Highly Pure Donepezil
ES2415166T3 (es)	2007-09-28	2013-07-24	Tianjin Hemay Bio-Tech Co., Ltd.	Polímorfos de sales de Donepezilo, métodos de preparación y usos de los mismos
US20090291127A1 (en) *	2008-05-21	2009-11-26	Jianye Wen	Transdermal anti-dementia active agent formulations and methods for using the same
BRPI0917862A2 (pt) *	2008-09-30	2015-11-24	Teikoku Pharma Usa Inc	composições transdérmicas de donepezil com distribuição prolongada e métodos para usar as mesmas
US20100178307A1 (en) *	2010-01-13	2010-07-15	Jianye Wen	Transdermal anti-dementia active agent formulations and methods for using the same
EP2366378A1 (en)	2010-03-01	2011-09-21	Dexcel Pharma Technologies Ltd.	Sustained-release donepezil formulations
US20140243278A1 (en) *	2011-07-05	2014-08-28	Sunil Sadanand Nadkarni	Acid Addition Salt of Donepezil and Pharmaceutical Composition Thereof
CN108976163B (zh) *	2017-06-05	2023-08-11	上海奥博生物医药股份有限公司	一种多奈哌齐双羟萘酸盐新的制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FI95572C (fi) *	1987-06-22	1996-02-26	Eisai Co Ltd	Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
DE69822218T2 (de) *	1997-12-05	2005-02-03	Eisai Co., Ltd.	Donepezil polykristalle und verfharen zu ihrer herstellung

2004
- 2004-06-29 US US10/879,816 patent/US7439365B2/en not_active Expired - Fee Related
- 2004-07-22 WO PCT/IN2004/000220 patent/WO2006001031A1/en active Application Filing
- 2004-07-22 AU AU2004320911A patent/AU2004320911A1/en not_active Abandoned
- 2004-07-22 KR KR1020067006534A patent/KR20060090245A/ko not_active Application Discontinuation
- 2004-07-22 EP EP04806734A patent/EP1761492B1/en active Active
- 2004-07-22 AT AT04806734T patent/ATE448203T1/de not_active IP Right Cessation
- 2004-07-22 JP JP2006537559A patent/JP2007536209A/ja not_active Withdrawn
- 2004-07-22 EA EA200700150A patent/EA200700150A1/ru unknown
- 2004-07-22 PT PT04806734T patent/PT1761492E/pt unknown
- 2004-07-22 CA CA2549752A patent/CA2549752C/en not_active Expired - Fee Related
- 2004-07-22 DE DE602004024129T patent/DE602004024129D1/de active Active
- 2004-07-22 PL PL04806734T patent/PL1761492T3/pl unknown
- 2004-07-22 CN CNA2004800318184A patent/CN1874998A/zh active Pending
- 2004-07-22 ES ES04806734T patent/ES2336572T3/es active Active
2006
- 2006-03-14 ZA ZA200602133A patent/ZA200602133B/en unknown

Also Published As

Publication number	Publication date
DE602004024129D1 (de)	2009-12-24
AU2004320911A1 (en)	2006-04-27
KR20060090245A (ko)	2006-08-10
EA200700150A1 (ru)	2007-08-31
JP2007536209A (ja)	2007-12-13
EP1761492B1 (en)	2009-11-11
US7439365B2 (en)	2008-10-21
US20050107613A1 (en)	2005-05-19
PL1761492T3 (pl)	2010-05-31
CA2549752C (en)	2010-04-13
EP1761492A1 (en)	2007-03-14
CA2549752A1 (en)	2006-01-05
PT1761492E (pt)	2010-02-18
CN1874998A (zh)	2006-12-06
ES2336572T3 (es)	2010-04-14
WO2006001031A1 (en)	2006-01-05
ATE448203T1 (de)	2009-11-15
AU2004320911A8 (en)	2008-08-21

Publication	Publication Date	Title
ZA200602133B (en)	2007-06-27	Novel salt of donepezil and its polymorphs (donepezi oxalate)
EP1048653B1 (en)	2004-03-03	Donepezil polycrystals and process for producing the same
CN101277969A (zh)	2008-10-01	亚氨基糖和氨基糖的纯化
CN1434800A (zh)	2003-08-06	吡啶－1－氧化物衍生物及其转化为药物活性化合物的方法
US20030212108A1 (en)	2003-11-13	Crystal modification
Hibbert et al.	1931	Studies on reactions relating to carbohydrates and polysaccharides. XXXIV. The constitution of levan and its relation to inulin
NZ207038A (en)	1986-05-09	Process for producing highly crystalline sodium cefoperazone
Schwarz et al.	1953	THREE MINOR ALKALOIDS OF GELSEMIUM SEMPERVIRENS AIT.
US3334014A (en)	1967-08-01	Dihydrofusidic acid
JPH02247151A (ja)	1990-10-02	シクロペンテノン誘導体の製法
NO159489B (no)	1988-09-26	Analogifremgangsmaate for fremstilling av farmakologisk aktive pyridazin-derivater.
US2905662A (en)	1959-09-22	Preparation of tetracycline-urea compound
WO2004099142A1 (en)	2004-11-18	Hydrobromide salt of benzyl-piperidylmethyl-indanone and its polymorphs
US6984725B2 (en)	2006-01-10	Method for the separation of triglycoalkaloids
JP2001500114A (ja)	2001-01-09	３―ヒドロキシメチルセファロスポリンの溶媒抽出法
CN1035005C (zh)	1997-05-28	制备6-(3-二甲氨基丙酰基)福司可林的新方法
NO157497B (no)	1987-12-21	Fremgangsm te for dekarbonylering av et alkylformat
WO2024062310A1 (en)	2024-03-28	Co-crystals derived from empagliflozin and dapagliflozin with l-proline
JPS58188878A (ja)	1983-11-04	メフロキンの精製方法
JPH02255692A (ja)	1990-10-16	Ｄ―グルコーｌ―グリセロ―３―オクチュロースの製造方法
JPH01246293A (ja)	1989-10-02	糖アルコール又はショ糖の脂肪酸エステルの精製方法
EP0427690A1 (en)	1991-05-15	Process for the preparation of heme/hemin
JP2000178294A (ja)	2000-06-27	ペンタアセチル―β―Ｄ―グルコ―スの製造方法
WO2006011154A1 (en)	2006-02-02	A novel polymorph of (1-benzyl-4-[(5,6-dimethoxy-1-indanone)-2-yl] methyl piperidine hydrochloride (donepezil hydrochloride) and a process for producing thereof
AU2003233261A1 (en)	2004-01-19	Method for the separation of triglycoalkaloids